CoChat

Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study

Open access
Hyams, Catherine, Marlow, Robin, Maseko, Zandile, King, Jade, Ward, Lana, Fox, Kazminder, Heath, Robyn, Tuner, Anabella, Friedrich, Zsolt, Morrison, Leigh, Ruffino, Gabriella, Antico, Rupert, Adegbite, David, Szasz-Benczur, Zsuzsa, Garcia Gonzalez, Maria, Oliver, Jennifer, Danon, Leon, Finn, Adam · 2021 · The Lancet Infectious Diseases
Cited by 131

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Background On Dec 8, 2020, deployment of the first SARS-CoV-2 vaccination authorised for UK use (BNT162b2 mRNA vaccine) began, followed by an adenoviral vector vaccine ChAdOx1 nCoV-19 on Jan 4, 2021. Care home residents and staff, frontline health-care workers, and adults aged 80 years and older were vaccinated first. However, few data exist regarding the effectiveness of these vaccines in older people with many comorbidities. In this post-implementation evaluation of two COVID-19 vaccines, we aimed to determine the effectiveness of one dose in reducing COVID-19-related admissions to hospital in people of advanced age. Methods This prospective test-negative case-control study included adults aged at least 80 years who were admitted to hospital in two NHS trusts in Bristol, UK with signs and symptoms of respiratory disease. Patients who developed symptoms before receiving their vaccine or those who received their vaccine after admission to hospital were excluded, as were those with symptoms that started more than 10 days before hospital admission. We did logistic regression analysis, controlling for time (week), sex, index of multiple deprivations, and care residency status, and sensitivity analyses matched for time and sex using a conditional logistic model adjusting for index of multiple deprivations and care residency status. This study is registered with ISRCTN, number 39557. Findings Between Dec 18, 2020, and Feb 26, 2021, 466 adults were eligible (144 test-positive and 322 test-negative). 18 (13%) of 135 people with SARS-CoV-2 infection and 90 (34%) of 269 controls received one dose of BNT162b2. The adjusted vaccine effectiveness was 71·4% (95% CI 46·5–90·6). Nine (25%) of 36 people with COVID-19 infection and 53 (59%) of 90 controls received one dose of ChAdOx1 nCoV-19. The adjusted vaccine effectiveness was 80·4% (95% CI 36·4–94·5). When BNT162b2 effectiveness analysis was restricted to the period covered by ChAdOx1 nCoV-19, the estimate was 79·3% (95% CI 47·0–92·5). Interpretation One dose of either BNT162b2 or ChAdOx1 nCoV-19 resulted in substantial risk reductions of COVID-19-related hospitalisation in people aged at least 80 years. Funding Pfizer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(21)00330-3

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 9

  1. Voysey, 2021, Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials, Lancet, 397, 881, 10.1016/S0140-6736(21)00432-3 · DOI · Paper page
  2. Verani, 2017, Case-control vaccine effectiveness studies: data collection, analysis and reporting results, Vaccine, 35, 3303, 10.1016/j.vaccine.2017.04.035 · DOI
  3. Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, 40, 373, 10.1016/0021-9681(87)90171-8 · DOI · Paper page
  4. Dupont, 1988, Power calculations for matched case-control studies, Biometrics, 44, 1157, 10.2307/2531743 · DOI · Paper page
  5. Pearce, 2016, Analysis of matched case-control studies, BMJ, 352, i969, 10.1136/bmj.i969 · DOI · Paper page
  6. Chodick, 2021, The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13–24 days after immunization: real-world evidence, medRxiv
  7. Wheelock, 2017, Evaluating the importance of policy amenable factors in explaining influenza vaccination: a cross-sectional multinational study, BMJ Open, 7, 10.1136/bmjopen-2016-014668 · DOI
  8. MacKenna, 2021, Trends, regional variation, and clinical characteristics of COVID-19 vaccine recipients: a retrospective cohort study in 23.4 million patients using OpenSAFELY, medRxiv
  9. Harper, 2021, Detecting SARS-CoV-2 variants with SNP genotyping, PLoS One, 16, 10.1371/journal.pone.0243185 · DOI

Cited by

See all 131

Metadata

Authors
Hyams, C., Marlow, R., Maseko, Z., King, J., Ward, L., Fox, K., Heath, R., Tuner, A., Friedrich, Z., Morrison, L., Ruffino, G., Antico, R., Adegbite, D., Szasz-Benczur, Z., Garcia Gonzalez, M., Oliver, J., Danon, L., & Finn, A.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2021-11
Volume
21
Issue
11
Pages
1539-1548
ISSN
1473-3099 (ISSN-L)
OpenAlex
W3176340533
Cited by
131
References
12
FWCI
9.62
Type
journal article
Language
en
Update notices
erratum (2021-08-01)
Open access
bronze
Funders
  • Bill and Melinda Gates Foundation
  • Medical Research Council (MC/PC/19067)
  • Pfizer
  • Engineering and Physical Sciences Research Council (EP/V051555/1)
  • Pfizer Inc Boulder
  • National Institute for Health Research
  • Janssen Pharmaceuticals
  • Alan Turing Institute (EP/N510129/1)
  • UK Research and Innovation (MR/V038613/1)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. https://app.cochat.ai/papers/10.1016/s1473-3099(21)00330-3
The paper
Hyams, C., Marlow, R., Maseko, Z., King, J., Ward, L., Fox, K., Heath, R., Tuner, A., Friedrich, Z., Morrison, L., Ruffino, G., Antico, R., Adegbite, D., Szasz-Benczur, Z., Garcia Gonzalez, M., Oliver, J., Danon, L., & Finn, A. (2021). Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(21)00330-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.